Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rxsight Inc (NQ: RXST )

48.67 +1.26 (+2.66%)
Streaming Delayed Price Updated: 10:24 AM EDT, Jul 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rxsight Inc

< Previous 1 2 3 4 Next >
RxSight, Inc. to Report Second Quarter Financial Results on August 5, 2024
From RxSight, Inc.
Via GlobeNewswire
Johnson & Johnson Q2 Earnings Preview: Can New Drugs Lift Sagging Stock?
Johnson & Johnson has beaten earnings per share in more than 10 straight quarters. Will the trend continue in Q2? 
Via Benzinga
RxSight Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Via Benzinga
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Why RxSight (RXST) Shares Are Falling
RxSight shares are trading lower by 5.6% during Thursday's session. The company announced pricing of its $100 million proposed public offering of common stock. 
Via Benzinga
RxSight, Inc. To Participate in the Truist Securities Medtech Conference
From RxSight, Inc.
Via GlobeNewswire
Do You Have Your Eye On Vision Care Stocks?
For investors seeking stable and growing opportunities, eye care stocks are an attractive option. 
Via Talk Markets
RxSight, Inc. Announces Closing of its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From RxSight, Inc.
Via GlobeNewswire
RxSight, Inc. Announces Pricing of Public Offering of Common Stock
From RxSight, Inc.
Via GlobeNewswire
What 10 Analyst Ratings Have To Say About RxSight
Via Benzinga
RxSight, Inc. Announces Proposed Public Offering of Common Stock
From RxSight, Inc.
Via GlobeNewswire
RXST Stock Earnings: RxSight Beats EPS, Beats Revenue for Q1 2024
RXST stock results show that RxSight beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
RxSight, Inc. Reports First Quarter 2024 Financial Results
From RxSight, Inc.
Via GlobeNewswire
Assessing RxSight: Insights From 8 Financial Analysts
Via Benzinga
Forecasting The Future: 9 Analyst Projections For RxSight
Via Benzinga
RxSight, Inc. to Present at the Bank of America Healthcare Conference
From RxSight, Inc.
Via GlobeNewswire
RxSight, Inc. to Report First Quarter Financial Results on May 6, 2024
From RxSight, Inc.
Via GlobeNewswire
RxSight Announces Commercial Launch of its Newest Light Adjustable Lens™, the LAL+™, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting
From RxSight, Inc.
Via GlobeNewswire
Recap: RxSight Q4 Earnings
Via Benzinga
RxSight's Earnings Outlook
Via Benzinga
Stifel Maintains Buy Rating for RxSight: Here's What You Need To Know
Via Benzinga
The Analyst Landscape: 8 Takes On RxSight
Via Benzinga
RxSight, Inc. to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From RxSight, Inc.
Via GlobeNewswire
Chart Of The Day: RxSight - Cashing In On Cataracts
Earnings are estimated to increase 33.30% this year, increase an additional 26.60% next year and continue to compound at an annual rate of 19.00% for the next 5 years 
Via Talk Markets
RxSight, Inc. to Participate in the 34th Annual Oppenheimer Healthcare Conference
From RxSight, Inc.
Via GlobeNewswire
RxSight, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
From RxSight, Inc.
Via GlobeNewswire
Earnings Scheduled For February 28, 2024
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion. 
Via Benzinga
RxSight, Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
From RxSight, Inc.
Via GlobeNewswire
Insiders are selling these hot stocks on track for higher prices
Insiders are selling these hot stocks and may cap gains in the near term, but long-term gains are in the outlook. Analysts support them and raise their targets. 
Via MarketBeat
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.